Liposomal methotrexate in the treatment of murine L1210 leukemia.
To assess the therapeutic effectiveness of methotrexate (MTX) when administered in a liposome carrier, mice bearing intracranial L1210 leukemia were tested with liposomal MTX, free MTX, or saline. Single i.p. injections of liposomal MTX at doses of 5 mg/kg and 2.5 mg/kg prolonged survival of mice bearing intracranial L1210 leukemia. The same doses of the free drug did not prolong survival of the tumor-bearing mice. This system may have clinical application not only for MTX, but also other polar anticancer agents in the treatment for central nervous system malignancy.
D000818:Animals; D001921:Brain / Q000378:metabolism; D007939:Leukemia L1210 / Q000188:drug therapy*; D008081:Liposomes / Q000008:administration & dosage*; D008727:Methotrexate / Q000008:administration & dosage* / Q000378:metabolism / Q000627:therapeutic use; D051379:Mice; D008815:Mice, Inbred Strains
D008081:Liposomes; D008727:Methotrexate